B-cell lymphoma (DLBCL). One in three people with lymphoma have this type, and it mainly affects older adults. It’s a fast-growing cancer that can start in your lymph nodes or related organs like your thymus, spleen, or tonsils. It usually responds well to treatment and is often cured...
CD19-Directed Antibody-Drug Conjugates for DLBCL | Case-Based Roundtable Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd Targeted Oncology Staff April 1st 2025 Article During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the...
“TDM-1 is the first therapy to show an improved survival after postsurgical therapy in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant therapy,” study author Sibylle Loibl, MD, PhD, of the German Breast Group in Neu-Isenburg, the Ce...
However, there is no known cause of nervous system cancer. Whether there is a genetic polymorphism which is crucial in a particular tumor type, or an involvement of toxins that regulate cell types at different stages of development remains unknown [50]. The very early onset of the disease ...
Extreme and recurrent tiredness is one of the common symptoms of most types of cancers. Tiredness is usually considered a warning sign of cancer progressing. Tiredness related to cancers usually does not get better with adequate rest or sleep.
more aggressive cancer phenotype, advanced disease stage and worse clinical outcome of various cancers including ovarian carcinoma, CRC, endometrial cancer, melanoma, cervical cancer, glioblastoma, lung adenocarcinoma, diffuse large B-cell lymphoma (DLBCL)[25,26,27,28,29, 31,32,33,34,35,36, 38]...
Chimeric antigen receptor (CAR) T-cell therapy is a relatively new kind of blood cancer treatment that uses the immune system to kill cancer cells. In some cases,CAR-T therapyhas cured patients where other treatments have failed. As CAR-T cells stay active in the body for a long period ...
Using this methodology, the reported prevalence of CVD was 16.2% in the overall cancer cohort and 7.7% in the breast cancer cohort, 22.1% in the colon cancer cohort, 16.8% in the rectal cancer cohort, 15.4% in the prostate cancer cohort, 36.1% in the NSCLC cohort, 21.7% in the DLBCL ...
more aggressive cancer phenotype, advanced disease stage and worse clinical outcome of various cancers including ovarian carcinoma, CRC, endometrial cancer, melanoma, cervical cancer, glioblastoma, lung adenocarcinoma, diffuse large B-cell lymphoma (DLBCL)[25,26,27,28,29, 31,32,33,34,35,36, 38]...
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer. According to Globaldata, it is involved in 2 clinical trials, which are ongoing.GlobalData uses proprietary data and analytics to provide a complete ...